By Farhat Nasim

Copyright medicaldialogues

New Delhi: Sanofi Ventures has announced a new USD 625 million multiyear capital commitment from Sanofi, increasing its total assets under management to over USD 1.4 billion. The additional funding is aimed at accelerating investments in biotech and digital health startups, particularly in areas aligned with Sanofi’s strategic focus: immunology, rare diseases, neurology, and vaccines.Paul Hudson, Chief Executive Officer of Sanofi, said, “This new, significant capital commitment reflects our strong belief that some of the most important medical breakthroughs begin in early-stage companies. By strengthening our investment capabilities, we are accelerating our ability to bring next-generation therapies that improve people’s lives while building valuable partnerships across the healthcare ecosystem.”Since its inception in 2012, Sanofi Ventures has deployed over $800 million across more than 70 companies in biotech and digital health. The venture fund participates in all stages of private company financing, from seed to crossover, serves on boards, and engages in IPOs. Jason P. Hafler, Managing Director at Sanofi Ventures, added, “The increased capital commitment enables us to deepen our role as a leading strategic investor in breakthrough science and digital innovation. Our global portfolio spans the full company lifecycle, demonstrating the long-term value we bring to both entrepreneurs and Sanofi.”The move comes at a time when early-stage funding for biotech companies is increasingly limited. By providing financial backing and strategic support, Sanofi Ventures aims to bridge the funding gap for promising startups, helping them advance therapies that could transform patient care globally.Sanofi Ventures’ expanded investment will not only strengthen Sanofi’s future pipeline but also reinforce the company’s position as a catalyst for innovation in healthcare. The fund focuses on pioneering companies that align with Sanofi’s long-term growth strategy, leveraging its expertise to drive scientific progress and long-term value creation.Sanofi is an R&D-driven, AI-powered biopharmaceutical company committed to improving people’s lives. The company develops medicines and vaccines targeting immune system-related diseases, rare conditions, neurology, and more, with an innovative pipeline designed to benefit millions worldwide.